Notice of EGM

Stem Cell Sciences plc
06 October 2006



Embargoed until 0700                                              6 October 2006

                             Stem Cell Sciences plc

                     Notice of EGM re Possible Dual Listing

The Directors of Stem Cell Sciences PLC ("SCS") or (the "Company"), the
biotechnology company focused on the commercialisation of stem cells and stem
cell technologies, today announced they were intending to dual list the
Company's Ordinary Shares on the Australian Stock Exchange ("ASX") whilst
continuing to trade on the AIM market of the London Stock Exchange ("AIM").

In conjunction with a listing, which the Directors believe will improve
liquidity in the stock, the Company intends to raise additional funds to support
the continued growth of the business.

The Directors have convened an extraordinary general meeting of the shareholders
of the Company for 1 November 2006 to seek the approval of the shareholders to
proceed with the proposed dual listing on the ASX, fund raising, to approve the
share sub-division and for any other related matters.

This announcement shall not constitute an offer to sell or the solicitation of
an offer to buy ordinary shares in any jurisdiction.

                                    - Ends -

For further information, please contact:

Stem Cell Sciences plc                                             0131 662 9829
Peter Mountford, President and CEO
Hugh Ilyine, Chief Operations Officer
Sue Furber, Director of Finance

Weber Shandwick | Square Mile                                      020 7067 0700
Rachel Taylor/Alex Brown









                      This information is provided by RNS
            The company news service from the London Stock Exchange